DexCom (NASDAQ:DXCM) Lowered to “Hold” at Baird R W

Baird R W downgraded shares of DexCom (NASDAQ:DXCM) from a strong-buy rating to a hold rating in a research note published on Friday, Zacks.com reports.

Other analysts have also recently issued reports about the stock. StockNews.com cut shares of DexCom from a buy rating to a hold rating in a report on Monday, June 10th. UBS Group lowered their target price on shares of DexCom from $163.00 to $95.00 and set a buy rating for the company in a research note on Friday. Raymond James upped their price target on DexCom from $151.00 to $160.00 and gave the stock a strong-buy rating in a research report on Friday, April 26th. Citigroup raised their price objective on DexCom from $148.00 to $161.00 and gave the stock a buy rating in a research report on Wednesday, April 3rd. Finally, Canaccord Genuity Group restated a buy rating and set a $145.00 target price on shares of DexCom in a research note on Tuesday, July 23rd. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus target price of $113.06.

DexCom Stock Down 40.7 %

Shares of NASDAQ DXCM opened at $64.00 on Friday. DexCom has a 12-month low of $62.34 and a 12-month high of $142.00. The stock’s fifty day simple moving average is $115.28 and its two-hundred day simple moving average is $123.76. The stock has a market capitalization of $25.45 billion, a PE ratio of 41.29, a price-to-earnings-growth ratio of 1.57 and a beta of 1.16. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. DexCom had a return on equity of 32.27% and a net margin of 16.95%. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same period in the prior year, the business posted $0.34 EPS. The firm’s quarterly revenue was up 15.3% on a year-over-year basis. As a group, analysts expect that DexCom will post 1.76 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Michael Jon Brown sold 659 shares of the firm’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the transaction, the executive vice president now owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Michael Jon Brown sold 659 shares of the company’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $114.29, for a total value of $75,317.11. Following the sale, the executive vice president now owns 66,901 shares in the company, valued at $7,646,115.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bridgette P. Heller sold 1,000 shares of DexCom stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total value of $113,550.00. Following the transaction, the director now owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,112 shares of company stock valued at $480,861. 0.30% of the stock is owned by insiders.

Hedge Funds Weigh In On DexCom

Large investors have recently made changes to their positions in the company. Crewe Advisors LLC acquired a new stake in DexCom during the first quarter valued at $29,000. DSM Capital Partners LLC acquired a new stake in shares of DexCom during the 4th quarter valued at about $28,000. Riverview Trust Co acquired a new stake in shares of DexCom during the 1st quarter valued at about $32,000. Valley National Advisers Inc. increased its stake in shares of DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. Finally, MV Capital Management Inc. raised its holdings in DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after purchasing an additional 138 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.